CLE Clinical Trials

2,006 recruitingLast updated: July 25, 2026

There are 2,006 actively recruiting cle clinical trials across 90 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include New York, New York, United States, Boston, Massachusetts, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


CLE Trials at a Glance

2,006 actively recruiting trials for cle are listed on ClinicalTrialsFinder across 6 cities in 90 countries. The largest study group is Not Applicable with 715 trials, with the heaviest enrollment activity in New York, Boston, and Houston. Lead sponsors running cle studies include Novartis Pharmaceuticals, M.D. Anderson Cancer Center, and Mayo Clinic.

Treatments under study

About CLE Clinical Trials

Looking for clinical trials for CLE? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new CLE trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about CLE clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 2,006 trials

Recruiting
Phase 2

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis

Focal Segmental Glomerulosclerosis
National Human Genome Research Institute (NHGRI)30 enrolled1 locationNCT06664814
Recruiting
Not Applicable

Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions

Arterial Occlusive DiseasesPainCardiovascular Diseases+12 more
Teleflex1,859 enrolled2 locationsNCT07258290
Recruiting
Phase 3

A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

Multiple Sclerosis (MS) Primary Progressive
Zenas BioPharma (USA), LLC705 enrolled33 locationsNCT07067463
Recruiting
Phase 1

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

Systemic SclerosisIdiopathic Inflammatory MyopathySystemic Lupus Erythematosus (With and Without Nephritis)
Allogene Therapeutics66 enrolled14 locationsNCT07085104
Recruiting
Phase 3

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated Carcinoma+5 more
National Cancer Institute (NCI)360 enrolled409 locationsNCT05256225
Recruiting
Phase 2

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Metastatic MelanomaMetastatic Renal Cell CarcinomaAdvanced Locoregional Melanoma+1 more
National Cancer Institute (NCI)78 enrolled1 locationNCT05155033
Recruiting
Phase 2

CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk

Metastatic Clear Cell Renal Cell Carcinoma
Jinling Hospital, China75 enrolled5 locationsNCT07615348
Recruiting

Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Amyotrophic Lateral SclerosisFrontotemporal DementiaProgressive Supranuclear Palsy
National Institute of Neurological Disorders and Stroke (NINDS)360 enrolled1 locationNCT03225144
Recruiting
Phase 3

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

Focal Segmental Glomerulosclerosis
Boehringer Ingelheim286 enrolled296 locationsNCT07220083
Recruiting

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders

Renal Cell CarcinomaKidney CancerClear Cell Renal Cancer+2 more
National Cancer Institute (NCI)5,000 enrolled1 locationNCT00001238
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Myasthenia GravisMultiple Sclerosis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company120 enrolled35 locationsNCT06220201
Recruiting
Phase 1Phase 2

Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

Advanced Clear Cell Renal Carcinoma (Ccrcc)Papillary Renal Cell Carcinoma (Prcc)
National Cancer Institute (NCI)100 enrolled1 locationNCT05665361
Recruiting
Not Applicable

Single Arm Trial Identifying Barriers and Facilitators to Mindfulness Practice

Multiple Sclerosis
University of Washington80 enrolled1 locationNCT07573241
Recruiting
Phase 3

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

ObesityOverweightAtherosclerotic Cardiovascular Disease
Amgen12,800 enrolled782 locationsNCT07037433
Recruiting
Phase 3

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

Amyotrophic Lateral Sclerosis
Prilenia500 enrolled44 locationsNCT07322003
Recruiting
Phase 3

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

Systemic Lupus Erythematosus (SLE)Cutaneous Lupus Erythematosus (CLE)
EMD Serono Research & Development Institute, Inc.202 enrolled13 locationsNCT07332481
Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled582 locationsNCT03866382
Recruiting

Toward Ubiquitous Lower Limb Exoskeleton Use in Children and Young Adults

Muscle WeaknessProblems Moving Their Arms and Legs
National Institutes of Health Clinical Center (CC)23 enrolled1 locationNCT06998134
Recruiting
Phase 3

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

Secondary Progressive Multiple Sclerosis
Zenas BioPharma (USA), LLC990 enrolled20 locationsNCT07299019
Recruiting
Not Applicable

Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP 2 (PALADIN2)

Amyotrophic Lateral Sclerosis(ALS)AutoantibodyPlasmapheresis
National Taiwan University Hospital20 enrolled1 locationNCT07726563